Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nasdaq  >  Rocket Pharmaceuticals, Inc.    RCKT

ROCKET PHARMACEUTICALS, INC.

(RCKT)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
10/19/2020 10/20/2020 10/21/2020 10/22/2020 10/23/2020 Date
28.16(c) 27.57(c) 27.5(c) 28.81(c) 28.105(c) Last
353 538 299 866 131 903 223 390 304 440 Volume
-2.90% -2.10% -0.25% +4.76% -2.45% Change
More quotes
Financials (USD)
Sales 2020 - - -
Net income 2020 -105 M - -
Net cash position 2020 286 M - -
P/E ratio 2020 -15,4x
Yield 2020 -
Sales 2021 9,30 M - -
Net income 2021 -130 M - -
Net cash position 2021 300 M - -
P/E ratio 2021 -13,4x
Yield 2021 -
Capitalization 1 590 M 1 590 M -
EV / Sales 2020 -
EV / Sales 2021 139x
Nbr of Employees 79
Free-Float 91,0%
More Financials
Company
Rocket Pharmaceuticals, Inc. is a clinical-stage biotechnology company. The Company is focused on developing gene therapy treatment options for rare, devastating diseases. The Company’s multi-platform development approach applies the well-established lentiviral vector (LVV) and adeno-associated viral vector (AAV) gene therapy platforms. The Company’s lead clinical program is a LVV-based gene therapy for the... 
More about the company
Notations Surperformance© of Rocket Pharmaceuticals, Inc.
Trading Rating : Investor Rating : -
More Ratings
All news about ROCKET PHARMACEUTICALS, INC.
10/19ROCKET PHARMACEUTICALS : Presents Positive LAD-l Clinical Update and Comprehensi..
AQ
10/16ROCKET PHARMACEUTICALS : nbsp;Presents Positive LAD-l Clinical Update and Compre..
BU
10/02ROCKET PHARMACEUTICALS : Announces Two Presentations at the European Society for..
AQ
10/01ROCKET PHARMACEUTICALS : Announces Two Presentations at the European Society for..
BU
09/25ROCKET PHARMACEUTICALS : Announces Participation at Upcoming Conferences
AQ
09/24ROCKET PHARMACEUTICALS : Announces Participation at Upcoming Conferences
BU
09/04ROCKET PHARMACEUTICALS : Announces Participation at Upcoming Conferences
BU
09/02ROCKET PHARMACEUTICALS : Announces First Patient Treated in Higher Dose Cohort i..
BU
08/27ROCKET PHARMACEUTICALS : Receives FDA Fast Track Designation for RP-L401 Gene Th..
BU
08/26ROCKET PHARMACEUTICALS : Expands Clinical Sites for its FA, Danon, LAD-I and IMO..
BU
08/05ROCKET PHARMACEUTICALS : Management's Discussion and Analysis of Financial Condi..
AQ
08/05ROCKET PHARMACEUTICALS : 2Q Earnings Snapshot
AQ
08/05ROCKET PHARMACEUTICALS : Reports Second Quarter 2020 Financial Results and Highl..
BU
07/13ROCKET PHARMACEUTICALS : Announces First Patient Treated in Phase 1 Trial of RP-..
BU
06/29ROCKET PHARMACEUTICALS : Announces FDA Clearance of IND for RP-L401 Gene Therapy..
BU
More news
News in other languages on ROCKET PHARMACEUTICALS, INC.

- No features available -

More news
Chart ROCKET PHARMACEUTICALS, INC.
Duration : Period :
Rocket Pharmaceuticals, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ROCKET PHARMACEUTICALS, INC.
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 12
Average target price 36,90 $
Last Close Price 28,81 $
Spread / Highest target 63,1%
Spread / Average Target 28,1%
Spread / Lowest Target 7,60%
EPS Revisions
Managers
NameTitle
Gaurav Shah President, Chief Executive Officer & Director
Roderick T. Wong Chairman
Kinnari Patel Chief Operating Officer & EVP-Development
Jonathan David Schwartz Chief Medical Officer & SVP-Clinical Development
Pedro P. Granadillo Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
ROCKET PHARMACEUTICALS, INC.26.58%1 590
GILEAD SCIENCES, INC.-6.63%76 063
REGENERON PHARMACEUTICALS53.33%60 584
VERTEX PHARMACEUTICALS-4.05%54 719
WUXI APPTEC CO., LTD.64.68%39 347
BEIGENE, LTD.83.27%27 531